RATIONALE: The alpha7 subtype of the nicotinic receptor plays an important role in auditory sensory gating. Schizophrenics show deficient sensory gating and abnormalities in the number and regulation of nicotinic receptors. Prepulse inhibition (PPI) deficits exhibited by isolation-reared rats are thought to model the sensorimotor gating deficits seen in schizophrenia. OBJECTIVE: To examine the role of nicotinic alpha7 receptors in the isolation-rearing rat model, we tested whether the selective alpha7 receptor agonist (R)-N-(1-Azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide) (compound A) could reverse isolation-rearing-induced PPI deficits, and investigated alpha7 receptor RNA expression in the hippocampus, prefrontal cortex, cerebellum, nucleus accumbens and thalamus, and alpha7 receptor protein expression in the hippocampus of isolation- and group-reared rats. METHOD: Rats reared in isolation or groups of five from weaning were tested in the PPI paradigm under conditions of variable inter-stimulus interval (ISI) (pulse = 110 dB/50 ms; prepulse = 75 dB/30 ms; ISI = 30, 100 and 300 ms) 30 min following administration of compound A (3.2-10 mg/kg i.p.). Alpha7 receptor expression was measured by TaqMan RT-PCR (total RNA) and autoradiography (protein). RESULTS: Isolation-rearing-induced PPI deficits were attenuated by both doses of compound A at 100-ms ISI and by 10 mg/kg at 300-ms ISI. Expression of alpha7 receptor RNA and protein was unaltered in isolation-reared rats. CONCLUSION: Although altered alpha7 receptor expression may not underlie the phenotype of isolation-reared rats, the activation of these receptors may be of benefit in re-establishing efficient gating function.
RATIONALE: The alpha7 subtype of the nicotinic receptor plays an important role in auditory sensory gating. Schizophrenics show deficient sensory gating and abnormalities in the number and regulation of nicotinic receptors. Prepulse inhibition (PPI) deficits exhibited by isolation-reared rats are thought to model the sensorimotor gating deficits seen in schizophrenia. OBJECTIVE: To examine the role of nicotinic alpha7 receptors in the isolation-rearing rat model, we tested whether the selective alpha7 receptor agonist (R)-N-(1-Azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide) (compound A) could reverse isolation-rearing-induced PPI deficits, and investigated alpha7 receptor RNA expression in the hippocampus, prefrontal cortex, cerebellum, nucleus accumbens and thalamus, and alpha7 receptor protein expression in the hippocampus of isolation- and group-reared rats. METHOD:Rats reared in isolation or groups of five from weaning were tested in the PPI paradigm under conditions of variable inter-stimulus interval (ISI) (pulse = 110 dB/50 ms; prepulse = 75 dB/30 ms; ISI = 30, 100 and 300 ms) 30 min following administration of compound A (3.2-10 mg/kg i.p.). Alpha7 receptor expression was measured by TaqMan RT-PCR (total RNA) and autoradiography (protein). RESULTS: Isolation-rearing-induced PPI deficits were attenuated by both doses of compound A at 100-ms ISI and by 10 mg/kg at 300-ms ISI. Expression of alpha7 receptor RNA and protein was unaltered in isolation-reared rats. CONCLUSION: Although altered alpha7 receptor expression may not underlie the phenotype of isolation-reared rats, the activation of these receptors may be of benefit in re-establishing efficient gating function.
Authors: S Leonard; J Gault; C Adams; C R Breese; Y Rollins; L E Adler; A Olincy; R Freedman Journal: Restor Neurol Neurosci Date: 1998-06 Impact factor: 2.406
Authors: Sherry Leonard; Judith Gault; Jan Hopkins; Judith Logel; Ruby Vianzon; Margaret Short; Carla Drebing; Ralph Berger; Diana Venn; Pinkhas Sirota; Gary Zerbe; Ann Olincy; Randal G Ross; Lawrence E Adler; Robert Freedman Journal: Arch Gen Psychiatry Date: 2002-12
Authors: A Parwani; E J Duncan; E Bartlett; S H Madonick; T R Efferen; R Rajan; M Sanfilipo; P B Chappell; S Chakravorty; S Gonzenbach; G N Ko; J P Rotrosen Journal: Biol Psychiatry Date: 2000-04-01 Impact factor: 13.382
Authors: A R Davies; D J Hardick; I S Blagbrough; B V Potter; A J Wolstenholme; S Wonnacott Journal: Neuropharmacology Date: 1999-05 Impact factor: 5.250
Authors: A J Grottick; G Trube; W A Corrigall; J Huwyler; P Malherbe; R Wyler; G A Higgins Journal: J Pharmacol Exp Ther Date: 2000-09 Impact factor: 4.030
Authors: Sung Won Kim; Yu-Shin Ding; David Alexoff; Vinal Patel; Jean Logan; Kuo-Shyan Lin; Colleen Shea; Lisa Muench; Youwen Xu; Pauline Carter; Payton King; Jasmine R Constanzo; James A Ciaccio; Joanna S Fowler Journal: Nucl Med Biol Date: 2007-07 Impact factor: 2.408
Authors: Tammy M K Cheng; Yu-En Lu; Paul C Guest; Hassan Rahmoune; Laura W Harris; Lan Wang; Dan Ma; Victoria Stelzhammer; Yagnesh Umrania; Matt T Wayland; Pietro Lió; Sabine Bahn Journal: Mol Cell Proteomics Date: 2009-12-10 Impact factor: 5.911
Authors: Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff Journal: Psychopharmacology (Berl) Date: 2008-06-21 Impact factor: 4.530
Authors: Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer Journal: Pharmacol Ther Date: 2009-03-06 Impact factor: 12.310